Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-HN: Docetaxel, Nimotuzumab, and Pucotenlimab in R/M HNSCC
NCT07354984Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab and nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pucotenlimabnimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07354984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354984.